OBIGEN PHARMA INC.

Obigen Pharma Inc is a Taiwan-based company mainly engaged in the research, design, development, manufacture and sale of novel botulinum toxin products. Its main product is typing A botulinum toxin, OBI-858, which is currently undergoing phase II clinical trials in Taiwan for the medical aesthetic indication of frown lines. It operates a complete supply chain for botulinum toxin OBI-858 in the Taiwanese market, encompassing research, development, and manufacturing, and collaborates with contract research organizations (CROs) to advance the development and clinical trials of the new drugs. Employees 60 Sector Biotechnology & Medical Research